Company: ATRA
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0000950170-25-072040
Chunk: 4

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1A
Chunk 4
---
 described above.

We expect to devote significant time and resources and to incur expenses in identifying and evaluating strategic alternatives for the company, which could have a material adverse effect on our business. A considerable portion of these expenses may be incurred regardless of whether a transaction is completed. Any such expenses will decrease the remaining cash available for use in our business. In addition, potential strategic transactions that require stockholder approval may not be approved by our stockholders or, if required, a counterparty’s stockholders. Further, any strategic transaction that is completed ultimately may not deliver the benefits we expect or enhance stockholder value.

Pursuing or consummating any strategic transaction may disrupt our management or business, require us to incur non-recurring or other charges, increase our near- and long-term expenditures, and may pose significant integration challenges, which could adversely affect our operations and financial results. For example, pursuing or consummating these transactions may entail numerous operational and financial risks, including:

•the inability to retain our key employees or our other service providers;

•increased volatility of our stock price;

•higher than anticipated transaction or integration costs;

•exposure to unknown liabilities;

•write downs of assets or goodwill or impairment charges;

•increased amortization expenses; and